Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Apr 15, 2024
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
Dec 16, 2014
Hemispherx's Ampligen® Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
Dec 09, 2014
Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen® Enlarged by Howard University Research
Nov 17, 2014
Ampligen® Blocks Critical Ebola Viral Disease (EVD) Protein Which Is Linked To High Mortality in Man
Nov 14, 2014
Hemispherx Biopharma Reports on Annual Stockholder Meeting
Nov 10, 2014
Hemispherx Biopharma Announces Financial Results for the Nine Months Ended September 30, 2014
Nov 03, 2014
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Collaborate on Alferon® and Ampligen® Against the Ebola Virus
Oct 30, 2014
Hemispherx Biopharma Reports New Evidence – Based Potential of Ampligen® Against Ebola Virus Disease (EVD)
Oct 20, 2014
Hemispherx Announces Strategic Relationship with Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola
Oct 20, 2014
Hemispherx Biopharma Prevails in Multi-Million Dollar Federal Lawsuit
1
2
3
4
5
<<
<
>
>>
Privacy